RemeGen Statistics

Total Valuation

RemeGen has a market cap or net worth of CNY 31.13 billion. The enterprise value is 33.10 billion.

Market Cap	31.13B
Enterprise Value	33.10B

Important Dates

The next estimated earnings date is Friday, August 15, 2025.

Earnings Date	Aug 15, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	355.03M
Shares Outstanding	n/a
Shares Change (YoY)	+0.51%
Shares Change (QoQ)	+3.03%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	329.17M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	16.28
PB Ratio	17.57
P/TBV Ratio	19.13
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-24.10
EV / Sales	17.65
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-30.42

Financial Position

The company has a current ratio of 0.92, with a Debt / Equity ratio of 1.54.

Current Ratio	0.92
Quick Ratio	0.56
Debt / Equity	1.54
Debt / EBITDA	n/a
Debt / FCF	-2.51
Interest Coverage	-16.30

Financial Efficiency

Return on equity (ROE) is -56.64% and return on invested capital (ROIC) is -17.74%.

Return on Equity (ROE)	-56.64%
Return on Assets (ROA)	-15.27%
Return on Invested Capital (ROIC)	-17.74%
Return on Capital Employed (ROCE)	-44.47%
Revenue Per Employee	637,678
Profits Per Employee	-458,014
Employee Count	2,999
Asset Turnover	0.35
Inventory Turnover	0.52

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +29.87% in the last 52 weeks. The beta is 0.67, so RemeGen's price volatility has been lower than the market average.

Beta (5Y)	0.67
52-Week Price Change	+29.87%
50-Day Moving Average	52.82
200-Day Moving Average	36.39
Relative Strength Index (RSI)	54.37
Average Volume (20 Days)	9,107,724

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, RemeGen had revenue of CNY 1.91 billion and -1.37 billion in losses. Loss per share was -2.54.

Revenue	1.91B
Gross Profit	1.55B
Operating Income	-1.32B
Pretax Income	-1.37B
Net Income	-1.37B
EBITDA	-1.07B
EBIT	-1.32B
Loss Per Share	-2.54

Full Income Statement

Balance Sheet

The company has 721.72 million in cash and 2.73 billion in debt, giving a net cash position of -2.01 billion.

Cash & Cash Equivalents	721.72M
Total Debt	2.73B
Net Cash	-2.01B
Net Cash Per Share	n/a
Equity (Book Value)	1.77B
Book Value Per Share	3.21
Working Capital	-184.17M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -876.33 million and capital expenditures -211.79 million, giving a free cash flow of -1.09 billion.

Operating Cash Flow	-876.33M
Capital Expenditures	-211.79M
Free Cash Flow	-1.09B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 81.16%, with operating and profit margins of -68.89% and -71.83%.

Gross Margin	81.16%
Operating Margin	-68.89%
Pretax Margin	-71.83%
Profit Margin	-71.83%
EBITDA Margin	-56.09%
EBIT Margin	-68.89%
FCF Margin	n/a

Dividends & Yields

RemeGen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.51%
Shareholder Yield	n/a
Earnings Yield	-4.41%
FCF Yield	-3.50%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RemeGen has an Altman Z-Score of 0.96 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.96
Piotroski F-Score	3